Trial Profile
Gemcitabine, Oxaliplatin and Capecitabine (GEMOXEL) for Patients With Advanced Pancreatic Adenocarcinoma (APC): A Phase I/II Study.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2010 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov.
- 13 Jan 2010 Actual patient number (46) added as reported by ClinicalTrials.gov.
- 13 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.